In a small trial, Mass General Brigham researchers have found that a drug designed to treat celiac disease supported a more rapid return to normal activities for patients following COVID.

In a phase 2 placebo-controlled study, children with multisystem inflammatory syndrome receiving larazotide recovered more rapidly.

In this Viewpoint, former members of the Advisory Committee on Immunization Practices (ACIP) caution that the sudden change in the ACIP may reverse the achievements of US immunization policy, includin...

A new study has identified distinct symptom patterns of long COVID in young children.

ExtractLong COVID, a post-acute infection syndrome triggered by SARS-CoV-2, is now recognised as a major cause of disability worldwide [1], affecting both children and adults. The World Health Organization (WHO) defines long COVID in children as: “new onset of symptoms impacting everyday functioning that last at least 2 months, occurring within 3 months of probable or confirmed acute SARS-CoV-2 infection” [2]. While elegantly designed clinical trials have been established to identify effective treatments for long COVID, children are notably excluded. We propose that inclusion of children in long COVID clinical trials is justified, and unwarranted age-related exclusion criteria for current clinical trial designs impose unintentional and unnecessary barriers to treatment for children with long COVID.

Multisystem inflammatory syndrome following SARS-CoV-2 infection results from increased serum levels of TGFβ, which impairs the reactivation of virus-specific T cells.